- PR Newswire•2 hours agoNektar Therapeutics to Host Investor & Analyst Conference Call to Discuss New Clinical Collaboration with Bristol-Myers Squibb
SAN FRANCISCO, Sept. 27, 2016 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced that it will host a conference call to discuss today's announcement of the new clinical collaboration with Bristol-Myers ...
- Reuters•2 hours ago
Bristol-Myers Squibb Co said on Tuesday it would evaluate the use of its blockbuster cancer immunotherapy Opdivo in combination with an experimental drug from Nektar Therapeutics to treat multiple cancers. The collaboration involves Nektar's NKTR-214, an experimental immuno-stimulatory therapy designed to increase the expression of PD-1 on immune cells. The trials will evaluate the potential for the combination to improve on the current standard-of-care to treat melanoma and cancers of the kidney, colorectal system, bladder and the most common form of lung cancer.
- American City Business Journals•2 hours ago
Bristol-Myers Squibb Co. will test its groundbreaking cancer immunotherapy drug Opdivo with an experimental cancer-fighting drug from Nektar Therapeutics Inc., the companies said Tuesday. The dollar value of the deal wasn't disclosed, but the companies will equally split third-party costs while absorbing their own costs as Opdivo and San Francisco-based Nektar (NKTR) see how the combination therapy works against a broad range of tumors. Opdivo is what's known as a checkpoint inhibitor, which remove the brakes that tumors trick the immune system into applying to help avoid detection.
Nektar Therapeutics (NKTR)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||18.45 x 800|
|Ask||19.50 x 500|
|Day's Range||17.41 - 18.76|
|52wk Range||9.92 - 19.98|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-18.36|
|Avg Vol (3m)||1,068,550|
|Dividend & Yield||N/A (N/A)|